Skip to main content English


Ursula Wiedermann-Schmidt
Univ. Prof. Dr. Ursula Wiedermann-Schmidt, MD, PhD, MScHead of Centre of Pathophysiology, Infectiology and Immunology, Head of Institute of Specific Prophylaxis and Tropical Medicine, Head of Outplatient Clinic for Vaccination, Travel- and Tropical Medici

Center for Pathophysiology, Infectiology and Immunology (Institute of Specific Prophylaxis and Tropical Medicine)
Position: Professor

ORCID: 0000-0002-1302-3223
T +43 1 40160 38290

Further Information


Allergy and Immunology; Vaccinology

Research group(s)

Research interests

Immunological tolerance induction and immunomodulation as treatment strategy for diseases with immunological hyper-responsiveness Development of new vaccines and vaccination strategies against infectious diseases, allergies and cancer Immunological characterization of vaccine responsiveness and vaccination failures Preclinical and clinical testing (Phase I-IV) of new vaccine candidates and adjuvant systems Host-pathogens interaction and microbiota-host interaction New concepts for needle less vaccines and novel adjuvants (e.g. mucosal delivery systems)

Techniques, methods & infrastructure

Development of new vaccines, Preclinical and clinical testing of new vaccines (Phase  I - IV), Outpatient Clinic for patients with immunological problems, Travel- and Tropical Medicine

Selected publications

  1. Wiedermann, U. et al., 2013. Impfungen für Mitarbeiter des Gesundheitswesens. Wiener klinische Wochenschrift, 126(S1), pp.11–22. Available at:
  2. Wagner, A. et al., 2015. Paediatricians require more information before they routinely co-administer the meningococcal B vaccine with routine infant vaccines. Acta Paediatrica, 104(10), pp.e439–e447. Available at:
  3. Wiedermann, U., Garner-Spitzer, E. & Wagner, A., 2016. Primary vaccine failure to routine vaccines: Why and what to do? Human Vaccines & Immunotherapeutics, 12(1), pp.239–243. Available at:
  4. Wiedermann, U. et al., 2016. Impfungen bei Immundefekten/Immunsuppression – Expertenstatement und Empfehlungen. Wiener klinische Wochenschrift, 128(S4), pp.337–376. Available at:
  5. Tobias, J. et al., 2017. Enhanced and long term immunogenicity of a Her-2/neu multi-epitope vaccine conjugated to the carrier CRM197 in conjunction with the adjuvant Montanide. BMC Cancer, 17(1). Available at: